Drug: |
||||
---|---|---|---|---|
Trial Name: |
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST) |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 08/01/2005 |
Age of Trial (yrs) 18.7 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
CAMN107A2103 |
|||
Sponsor: |
Novartis |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
This phase I trial combined AMN107 (nilotinib) with Gleevec. AMN107 as a single agent was selected for a phase III registration trial for third-line therapy. |
Trial Links |
Trial Results |
Name |
Address |
City |
State |
Zip |
Country |
450 Brookline Ave |
Boston |
MA |
02215-5450 |
USA |
|
333 Cottman Ave |
Philadelphia |
PA |
19111 |
USA |